GSK - FibroGen: Updates To Thesis Clinical And Regulatory Catalysts Loom
Shares of FibroGen (FGEN) have risen by 80% since I called the stock a Strong Buy back in 2016, noting that lead program roxadustat (a hypoxia-inducible factor-prolyl hydroxylase or HIF-PH inhibitor) offers several benefits over conventional injectable anemia treatments, including reductions in cardiovascular events and cost effectiveness due to the reduction or elimination of other commonly used medicines to treat the condition. On the other hand, shares have lost over 20% of their value since my August 2017 update.
My initial thought is that with important regulatory submissions coming up in the